Centers for Disease Control and Prevention (CDC) Research Centers for Disease Control and Prevention (CDC) RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Balanced on the Biggest Wave: Nirsevimab for Newborns
Neonatal Netw. 2024 Apr 1;43(2):105-115. doi: 10.1891/NN-2023-0056.ABSTRACTRespiratory syncytial virus (RSV) is the leading cause of hospitalization in infancy in the United States. Nearly all infants are infected by 2 years of age, with bronchiolitis requiring hospitalization often occurring in previously healthy children and long-term consequences of severe disease including delayed speech development and asthma. Incomplete passage of maternal immunity and a high degree of genetic variability within the virus contribute to morbidity and have also prevented successful neonatal vaccine development. Monoclonal antibodies re...
Source: Neonatal Network - April 10, 2024 Category: Perinatology & Neonatology Authors: Christopher McPherson Christine R Lockowitz Jason G Newland Source Type: research

Balanced on the Biggest Wave: Nirsevimab for Newborns
Neonatal Netw. 2024 Apr 1;43(2):105-115. doi: 10.1891/NN-2023-0056.ABSTRACTRespiratory syncytial virus (RSV) is the leading cause of hospitalization in infancy in the United States. Nearly all infants are infected by 2 years of age, with bronchiolitis requiring hospitalization often occurring in previously healthy children and long-term consequences of severe disease including delayed speech development and asthma. Incomplete passage of maternal immunity and a high degree of genetic variability within the virus contribute to morbidity and have also prevented successful neonatal vaccine development. Monoclonal antibodies re...
Source: Neonatal Network - April 10, 2024 Category: Perinatology & Neonatology Authors: Christopher McPherson Christine R Lockowitz Jason G Newland Source Type: research

Balanced on the Biggest Wave: Nirsevimab for Newborns
Neonatal Netw. 2024 Apr 1;43(2):105-115. doi: 10.1891/NN-2023-0056.ABSTRACTRespiratory syncytial virus (RSV) is the leading cause of hospitalization in infancy in the United States. Nearly all infants are infected by 2 years of age, with bronchiolitis requiring hospitalization often occurring in previously healthy children and long-term consequences of severe disease including delayed speech development and asthma. Incomplete passage of maternal immunity and a high degree of genetic variability within the virus contribute to morbidity and have also prevented successful neonatal vaccine development. Monoclonal antibodies re...
Source: Neonatal Network - April 10, 2024 Category: Perinatology & Neonatology Authors: Christopher McPherson Christine R Lockowitz Jason G Newland Source Type: research

Balanced on the Biggest Wave: Nirsevimab for Newborns
Neonatal Netw. 2024 Apr 1;43(2):105-115. doi: 10.1891/NN-2023-0056.ABSTRACTRespiratory syncytial virus (RSV) is the leading cause of hospitalization in infancy in the United States. Nearly all infants are infected by 2 years of age, with bronchiolitis requiring hospitalization often occurring in previously healthy children and long-term consequences of severe disease including delayed speech development and asthma. Incomplete passage of maternal immunity and a high degree of genetic variability within the virus contribute to morbidity and have also prevented successful neonatal vaccine development. Monoclonal antibodies re...
Source: Neonatal Network - April 10, 2024 Category: Perinatology & Neonatology Authors: Christopher McPherson Christine R Lockowitz Jason G Newland Source Type: research

Balanced on the Biggest Wave: Nirsevimab for Newborns
Neonatal Netw. 2024 Apr 1;43(2):105-115. doi: 10.1891/NN-2023-0056.ABSTRACTRespiratory syncytial virus (RSV) is the leading cause of hospitalization in infancy in the United States. Nearly all infants are infected by 2 years of age, with bronchiolitis requiring hospitalization often occurring in previously healthy children and long-term consequences of severe disease including delayed speech development and asthma. Incomplete passage of maternal immunity and a high degree of genetic variability within the virus contribute to morbidity and have also prevented successful neonatal vaccine development. Monoclonal antibodies re...
Source: Neonatal Network - April 10, 2024 Category: Perinatology & Neonatology Authors: Christopher McPherson Christine R Lockowitz Jason G Newland Source Type: research

Balanced on the Biggest Wave: Nirsevimab for Newborns
Neonatal Netw. 2024 Apr 1;43(2):105-115. doi: 10.1891/NN-2023-0056.ABSTRACTRespiratory syncytial virus (RSV) is the leading cause of hospitalization in infancy in the United States. Nearly all infants are infected by 2 years of age, with bronchiolitis requiring hospitalization often occurring in previously healthy children and long-term consequences of severe disease including delayed speech development and asthma. Incomplete passage of maternal immunity and a high degree of genetic variability within the virus contribute to morbidity and have also prevented successful neonatal vaccine development. Monoclonal antibodies re...
Source: Neonatal Network - April 10, 2024 Category: Perinatology & Neonatology Authors: Christopher McPherson Christine R Lockowitz Jason G Newland Source Type: research

Balanced on the Biggest Wave: Nirsevimab for Newborns
Neonatal Netw. 2024 Apr 1;43(2):105-115. doi: 10.1891/NN-2023-0056.ABSTRACTRespiratory syncytial virus (RSV) is the leading cause of hospitalization in infancy in the United States. Nearly all infants are infected by 2 years of age, with bronchiolitis requiring hospitalization often occurring in previously healthy children and long-term consequences of severe disease including delayed speech development and asthma. Incomplete passage of maternal immunity and a high degree of genetic variability within the virus contribute to morbidity and have also prevented successful neonatal vaccine development. Monoclonal antibodies re...
Source: Neonatal Network - April 10, 2024 Category: Perinatology & Neonatology Authors: Christopher McPherson Christine R Lockowitz Jason G Newland Source Type: research

Balanced on the Biggest Wave: Nirsevimab for Newborns
Neonatal Netw. 2024 Apr 1;43(2):105-115. doi: 10.1891/NN-2023-0056.ABSTRACTRespiratory syncytial virus (RSV) is the leading cause of hospitalization in infancy in the United States. Nearly all infants are infected by 2 years of age, with bronchiolitis requiring hospitalization often occurring in previously healthy children and long-term consequences of severe disease including delayed speech development and asthma. Incomplete passage of maternal immunity and a high degree of genetic variability within the virus contribute to morbidity and have also prevented successful neonatal vaccine development. Monoclonal antibodies re...
Source: Neonatal Network - April 10, 2024 Category: Perinatology & Neonatology Authors: Christopher McPherson Christine R Lockowitz Jason G Newland Source Type: research

Balanced on the Biggest Wave: Nirsevimab for Newborns
Neonatal Netw. 2024 Apr 1;43(2):105-115. doi: 10.1891/NN-2023-0056.ABSTRACTRespiratory syncytial virus (RSV) is the leading cause of hospitalization in infancy in the United States. Nearly all infants are infected by 2 years of age, with bronchiolitis requiring hospitalization often occurring in previously healthy children and long-term consequences of severe disease including delayed speech development and asthma. Incomplete passage of maternal immunity and a high degree of genetic variability within the virus contribute to morbidity and have also prevented successful neonatal vaccine development. Monoclonal antibodies re...
Source: Neonatal Network - April 10, 2024 Category: Perinatology & Neonatology Authors: Christopher McPherson Christine R Lockowitz Jason G Newland Source Type: research

How Would You Manage HIV Pre-exposure Prophylaxis in This Patient With Medical Comorbidities? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center
Ann Intern Med. 2024 Apr 9. doi: 10.7326/M24-0217. Online ahead of print.ABSTRACTDespite advances in treatment, HIV infection remains an important cause of morbidity and mortality, with more than 30 000 new cases diagnosed in the United States each year. There are several interventions traditionally used to prevent HIV transmission, but these vary in effectiveness and there are challenges to their implementation. In 2014, the Centers for Disease Control and Prevention published initial guidance on the use of antiretroviral pre-exposure prophylaxis (PrEP) to prevent transmission of HIV infection in persons at risk based on ...
Source: Annals of Internal Medicine - April 8, 2024 Category: Internal Medicine Authors: Howard Libman Douglas Krakower Jessica L Taylor Risa B Burns Source Type: research

How Would You Manage HIV Pre-exposure Prophylaxis in This Patient With Medical Comorbidities? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center
Ann Intern Med. 2024 Apr 9. doi: 10.7326/M24-0217. Online ahead of print.ABSTRACTDespite advances in treatment, HIV infection remains an important cause of morbidity and mortality, with more than 30 000 new cases diagnosed in the United States each year. There are several interventions traditionally used to prevent HIV transmission, but these vary in effectiveness and there are challenges to their implementation. In 2014, the Centers for Disease Control and Prevention published initial guidance on the use of antiretroviral pre-exposure prophylaxis (PrEP) to prevent transmission of HIV infection in persons at risk based on ...
Source: Annals of Internal Medicine - April 8, 2024 Category: Internal Medicine Authors: Howard Libman Douglas Krakower Jessica L Taylor Risa B Burns Source Type: research

How Would You Manage HIV Pre-exposure Prophylaxis in This Patient With Medical Comorbidities? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center
Ann Intern Med. 2024 Apr 9. doi: 10.7326/M24-0217. Online ahead of print.ABSTRACTDespite advances in treatment, HIV infection remains an important cause of morbidity and mortality, with more than 30 000 new cases diagnosed in the United States each year. There are several interventions traditionally used to prevent HIV transmission, but these vary in effectiveness and there are challenges to their implementation. In 2014, the Centers for Disease Control and Prevention published initial guidance on the use of antiretroviral pre-exposure prophylaxis (PrEP) to prevent transmission of HIV infection in persons at risk based on ...
Source: Annals of Internal Medicine - April 8, 2024 Category: Internal Medicine Authors: Howard Libman Douglas Krakower Jessica L Taylor Risa B Burns Source Type: research

How Would You Manage HIV Pre-exposure Prophylaxis in This Patient With Medical Comorbidities? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center
Ann Intern Med. 2024 Apr 9. doi: 10.7326/M24-0217. Online ahead of print.ABSTRACTDespite advances in treatment, HIV infection remains an important cause of morbidity and mortality, with more than 30 000 new cases diagnosed in the United States each year. There are several interventions traditionally used to prevent HIV transmission, but these vary in effectiveness and there are challenges to their implementation. In 2014, the Centers for Disease Control and Prevention published initial guidance on the use of antiretroviral pre-exposure prophylaxis (PrEP) to prevent transmission of HIV infection in persons at risk based on ...
Source: Annals of Internal Medicine - April 8, 2024 Category: Internal Medicine Authors: Howard Libman Douglas Krakower Jessica L Taylor Risa B Burns Source Type: research

How Would You Manage HIV Pre-exposure Prophylaxis in This Patient With Medical Comorbidities? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center
Ann Intern Med. 2024 Apr;177(4):518-526. doi: 10.7326/M24-0217. Epub 2024 Apr 9.ABSTRACTDespite advances in treatment, HIV infection remains an important cause of morbidity and mortality, with more than 30 000 new cases diagnosed in the United States each year. There are several interventions traditionally used to prevent HIV transmission, but these vary in effectiveness and there are challenges to their implementation. In 2014, the Centers for Disease Control and Prevention published initial guidance on the use of antiretroviral pre-exposure prophylaxis (PrEP) to prevent transmission of HIV infection in persons at risk ba...
Source: Annals of Internal Medicine - April 8, 2024 Category: Internal Medicine Authors: Howard Libman Douglas Krakower Jessica L Taylor Risa B Burns Source Type: research

A case of congenital rubella syndrome and epidemiology of related cases in China, 2014 –2023
Volume 20, Issue 1, December 2024 . (Source: Human Vaccines and Immunotherapeutics)
Source: Human Vaccines and Immunotherapeutics - April 8, 2024 Category: Allergy & Immunology Authors: Xiaoying GongCanjie ZhengQuanjun FangWenjie XuZhiying YinDepartment of Immunity, Quzhou Center for Disease Control and Prevention, Quzhou, Zhejiang, China Source Type: research